Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Year | Receivables | Debt | Liabilities | Assets | Current Assets |
---|---|---|---|---|---|
2023 | -358,281,000 | 22.88 M | 368 M | 365.66 M | |
2022 | -193,277,000 | 23.61 M | 200.21 M | 198.49 M | |
2021 | -86,383,000 | 156.61 M | 92.41 M | 90.48 M | |
2020 | 20.43 M | 4.82 M | 122.09 M | 1.34 M |